Data gathered: April 15
AI Stock Analysis - Ardelyx (ARDX)
Analysis generated March 4, 2025. Powered by Chat GPT.
Ardelyx is a company operating in the biopharmaceutical industry with a focus on the development and commercialization of innovative medicines. Their mission is to address unmet medical needs, primarily in the area of unmet medical needs in kidney and metabolic diseases, as well as gastrointestinal disorders. The company has achieved numerous milestones in its product development pipeline and continues to push forward with new innovations. As of today, Ardelyx is trading with a stock price of $5.41.
Stock Alerts - Ardelyx (ARDX)
 |
Ardelyx | April 10 Price is down by -5.6% in the last 24h. |
|
Ardelyx | April 9 Price is down by -5.1% in the last 24h. |
|
Ardelyx | April 9 Insider Alert: RAAB MICHAEL is selling shares |
|
Ardelyx | April 8 Price is up by 5.8% in the last 24h. |
Alternative Data for Ardelyx
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 27 | Sign up | Sign up | Sign up |
| Sentiment | 92 | Sign up | Sign up | Sign up |
| Webpage traffic | 12,000 | Sign up | Sign up | Sign up |
| Employee Rating | 82 | Sign up | Sign up | Sign up |
| Google Trends | 21 | Sign up | Sign up | Sign up |
| Patents | 33 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 9 | Sign up | Sign up | Sign up |
| Facebook Followers | 227 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 245 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 18,657 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,741 | Sign up | Sign up | Sign up |
| Twitter Mentions | 108 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 64 | Sign up | Sign up | Sign up |
| Linkedin Employees | 423 | Sign up | Sign up | Sign up |
About Ardelyx
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally.
| Price | $4.57 |
| Target Price | Sign up |
| Volume | 4,060,000 |
| Market Cap | $1.06B |
| Year Range | $4.25 - $6.93 |
| Dividend Yield | 0% |
| Analyst Rating | 60% buy |
| Industry | Biotechnology |
In the news
 |
Orion Portfolio Solutions LLC Boosts Position in Ardelyx, Inc. (NASDAQ:ARDX)April 12 - ETF Daily News |
|
Ardelyx Sees Unusually Large Options Volume (NASDAQ:ARDX)April 10 - ETF Daily News |
|
Ardelyx, Inc. (NASDAQ:ARDX) Shares Acquired by Teacher Retirement System of TexasApril 1 - ETF Daily News |
Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical MeetingsMarch 31 - Finnhub |
|
|
Cibc World Markets Corp Makes New $112,000 Investment in Ardelyx, Inc. (NASDAQ:ARDX)March 28 - ETF Daily News |
|
Analysts Set Ardelyx, Inc. (NASDAQ:ARDX) Price Target at $10.95March 24 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '24 | 116M | 18M | 98M | 4.6M | 11M | 0.020 |
| Q3 '24 | 98M | 16M | 83M | -810,000 | 5.1M | -0.003 |
| Q2 '24 | 73M | 10M | 63M | -16M | -11M | -0.070 |
| Q1 '24 | 46M | 7.6M | 38M | -27M | -22M | -0.110 |
| Q4 '23 | 34M | 5.1M | 29M | -29M | -25M | -0.120 |
Insider Transactions View All
| RAAB MICHAEL filed to sell 1,615,587 shares at $4.6. April 8 '25 |
| RAAB MICHAEL filed to sell 1,635,138 shares at $5.4. March 7 '25 |
| MOTT DAVID M filed to buy 2,015,494 shares at $5. February 26 '25 |
| GRAMMER ELIZABETH A filed to sell 181,043 shares at $5.6. February 21 '25 |
| Renz Justin A filed to sell 285,968 shares at $5.6. February 21 '25 |
Similar companies
Read more about Ardelyx (ARDX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Ardelyx?
The Market Cap of Ardelyx is $1.06B.
What is the current stock price of Ardelyx?
Currently, the price of one share of Ardelyx stock is $4.57.
How can I analyze the ARDX stock price chart for investment decisions?
The ARDX stock price chart above provides a comprehensive visual representation of Ardelyx's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Ardelyx shares. Our platform offers an up-to-date ARDX stock price chart, along with technical data analysis and alternative data insights.
Does ARDX offer dividends to its shareholders?
As of our latest update, Ardelyx (ARDX) does not offer dividends to its shareholders. Investors interested in Ardelyx should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Ardelyx?
Some of the similar stocks of Ardelyx are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.